Jasper Therapeutics Inc. Common Stock JSPR · Stock Open Jasper Therapeutics Inc. Common Stock in new tab
Jasper Therapeutics Inc. Common Stock Analysis (JSPR)
Is Jasper Therapeutics Inc. Common Stock a good investment? Jasper Therapeutics Inc. Common Stock (JSPR) is currently trading at 0.6063 USD. Market analysts have a consensus price target of 9.17 USD. This suggests a potential upside from current levels.
Earnings Schedule: Jasper Therapeutics Inc. Common Stock is expected to release its next earnings report on Aug. 7, 2026. The market consensus estimate for Forward EPS is -2.56.
Investor FAQ
Does Jasper Therapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Jasper Therapeutics Inc. Common Stock?
Jasper Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 7, 2026. The company currently has a trailing EPS of -2.58.
Company Profile
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.
| Split Date | Split Ratio to 1 |
|---|---|
| Jan. 4, 2024 | 0.100000 |
Community Discussion